L-Centchroman (ormeloxifene) is a non-steroidal selective estrogen receptor modulator (SERM) primarily used as an oral contraceptive, offering an effective alternative to steroidal hormonal methods. It works by binding to estrogen receptors, exerting tissue-specific effects: anti-estrogenic in the endometrium to prevent implantation and in the cervix to thicken mucus, while potentially sparing ovulation in many cycles. This selective modulation minimizes disruption to overall hormonal balance. It has been studied for its anti-estrogenic potential in managing hormone-receptor-positive breast cancer and may help maintain bone density to reduce osteoporosis risk in postmenopausal women. Its extended half-life supports less frequent dosing (typically weekly), improving adherence. Suitable for women seeking non-steroidal options, but use requires medical supervision to monitor for side effects.